[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2863275B1 - Procede pour le diagnostic/pronostic du cancer du sein - Google Patents

Procede pour le diagnostic/pronostic du cancer du sein

Info

Publication number
FR2863275B1
FR2863275B1 FR0314364A FR0314364A FR2863275B1 FR 2863275 B1 FR2863275 B1 FR 2863275B1 FR 0314364 A FR0314364 A FR 0314364A FR 0314364 A FR0314364 A FR 0314364A FR 2863275 B1 FR2863275 B1 FR 2863275B1
Authority
FR
France
Prior art keywords
prognosis
diagnosis
breast cancer
breast
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0314364A
Other languages
English (en)
Other versions
FR2863275A1 (fr
Inventor
Thibaut Verjat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA filed Critical Biomerieux SA
Priority to FR0314364A priority Critical patent/FR2863275B1/fr
Priority to EP04816515A priority patent/EP1694868A2/fr
Priority to PCT/FR2004/050661 priority patent/WO2005056829A2/fr
Priority to US10/579,986 priority patent/US20070134669A1/en
Priority to CNA2004800367443A priority patent/CN1890387A/zh
Publication of FR2863275A1 publication Critical patent/FR2863275A1/fr
Application granted granted Critical
Publication of FR2863275B1 publication Critical patent/FR2863275B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR0314364A 2003-12-09 2003-12-09 Procede pour le diagnostic/pronostic du cancer du sein Expired - Fee Related FR2863275B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0314364A FR2863275B1 (fr) 2003-12-09 2003-12-09 Procede pour le diagnostic/pronostic du cancer du sein
EP04816515A EP1694868A2 (fr) 2003-12-09 2004-12-07 Procede pour le diagnostic/pronostic du cancer du sein
PCT/FR2004/050661 WO2005056829A2 (fr) 2003-12-09 2004-12-07 Procede pour le diagnostic/pronostic du cancer du sein
US10/579,986 US20070134669A1 (en) 2003-12-09 2004-12-07 Method for diagnosis/prognosis of breast cancer
CNA2004800367443A CN1890387A (zh) 2003-12-09 2004-12-07 用于乳腺癌的诊断/预后的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0314364A FR2863275B1 (fr) 2003-12-09 2003-12-09 Procede pour le diagnostic/pronostic du cancer du sein

Publications (2)

Publication Number Publication Date
FR2863275A1 FR2863275A1 (fr) 2005-06-10
FR2863275B1 true FR2863275B1 (fr) 2007-08-10

Family

ID=34586373

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0314364A Expired - Fee Related FR2863275B1 (fr) 2003-12-09 2003-12-09 Procede pour le diagnostic/pronostic du cancer du sein

Country Status (5)

Country Link
US (1) US20070134669A1 (fr)
EP (1) EP1694868A2 (fr)
CN (1) CN1890387A (fr)
FR (1) FR2863275B1 (fr)
WO (1) WO2005056829A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006001701D1 (de) * 2005-08-01 2008-08-21 Sysmex Corp Verfahren zur Beurteilung der Beschaffenheit maligner Tumore
WO2008145125A1 (fr) * 2007-05-31 2008-12-04 Dako Denmark A/S Procédés d'utilisation des changements du nombre de copies d'esr dans les traitements et les pronostics du cancer du sein
NZ584848A (en) 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US20090203015A1 (en) * 2008-02-13 2009-08-13 Celera Corporation Multiplex assays for hormonal and growth factor receptors, and uses thereof
ES2482692T3 (es) * 2008-05-12 2014-08-04 Genomic Health, Inc. Pruebas para predecir la receptividad de pacientes con cáncer a opciones de tratamiento con quimioterapia
UA110790C2 (uk) * 2010-03-31 2016-02-25 Сівідон Діагностікс Гмбх Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні
CN101921858B (zh) * 2010-08-23 2013-08-28 广州益善生物技术有限公司 乳腺癌预后相关基因mRNA表达水平检测液相芯片
CN102703591B (zh) * 2012-05-30 2014-04-23 北京艾迪康医学检验所有限公司 用于雌激素受体α基因内含子1 P vuII 和X baI 多态性焦磷酸检测的引物
CN112646864A (zh) * 2020-12-30 2021-04-13 杭州联川基因诊断技术有限公司 一种检测esr1基因表达的引物、探针、试剂盒和检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672040A (en) * 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5750338A (en) * 1986-10-23 1998-05-12 Amoco Corporation Target and background capture methods with amplification for affinity assays
US4863202A (en) * 1987-09-16 1989-09-05 Oldford William G Fluid connector assembly
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5234809A (en) * 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
CA2020958C (fr) * 1989-07-11 2005-01-11 Daniel L. Kacian Methodes d'amplification de sequences d'acide nucleique
US5545522A (en) * 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO2001042307A1 (fr) * 1999-12-07 2001-06-14 Sumitomo Chemical Company, Limited ERα MUTANTS ET SYSTEME DE TEST POUR TRANSACTIVATION
AU3458401A (en) * 2000-01-25 2001-08-07 Genentech Inc. Compositions and methods for treatment of cancer
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AU2002307466A1 (en) * 2001-04-20 2002-11-05 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies
AUPS337802A0 (en) * 2002-07-04 2002-07-25 Fujisawa Pharmaceutical Co., Ltd. Method of screening for antidiabetic agents

Also Published As

Publication number Publication date
WO2005056829A3 (fr) 2005-11-17
CN1890387A (zh) 2007-01-03
EP1694868A2 (fr) 2006-08-30
US20070134669A1 (en) 2007-06-14
FR2863275A1 (fr) 2005-06-10
WO2005056829A2 (fr) 2005-06-23

Similar Documents

Publication Publication Date Title
EP1937845A4 (fr) Procédés et compositions à base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
EP1930426A4 (fr) Composition et procede de diagnostic d'un cancer du rein et d'evaluation du pronostic vital d' un patient atteint de cancer du rein
FR2919060B1 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
DE602004024630D1 (de) Ultraschalldiagnosegerät
DE602004023991D1 (de) Ultraschalldiagnosegerät
IL180997A0 (en) Diagnostic methods and kits utilizing platelet biomarkers for cancer
ZA200710297B (en) Method for the segmentation of leukocytes
AU2002349786A8 (en) Method for diagnosis of colorectal tumors
FR2869698B1 (fr) Procede pour le controle et le diagnostic de machines
EP1590433A4 (fr) Diagnostic et pronostic de patients souffrant de cancer du sein
FR2896881B1 (fr) Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
FR2864301B1 (fr) Systeme et procede de tomosynthese radioscopique
IL179715A0 (en) Diagnosing or predicting the course of breast cancer
FR2855836B1 (fr) Procede pour la preparation de composants metalliques pre-enduits et composants prepares de cette facon
FR2919064B1 (fr) Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919065B1 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
SI1766056T1 (sl) Oligonukleotidi za diagnozo raka na prsih
EP1782310A4 (fr) Procede de mesure de l'incidence des infections nosocomiales
FR2909207B1 (fr) Procede de visualisation tridimensionnelle d'images de tomosynthese en mammographie.
FR2891379B1 (fr) Procede et systeme de diagnostic des pannes pour aerodynes
DE602004008966D1 (de) N-arylhydrazonderivate für die saatgutbehandlung
EP1862804A4 (fr) Méthode pour diagnostiquer le cancer de la prostate
FR2863275B1 (fr) Procede pour le diagnostic/pronostic du cancer du sein
FR2906287B1 (fr) Installation pour la pratique d'activites aquatiques
EP1952138A4 (fr) Methode de depistage d'une maladie inflammatoire ou d'un cancer

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110831